Targeting fundamentals of inflammation, autoimmunity and fibrosis
Granite Bio Debuts With $100 Million of Capital
–
Granite Bio Debuts With $100 Million of Capital –
Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology.
-
GRT-001
Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.
-
GRT-002
Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.
Two first-in-class therapeutic antibodies GRT-001 and GRT-002
Team:
Granite Bio Team:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Sonia Whitlow
Toxicology Study Monitor
-
Kai Rosport
CMC, Ridgeline Discovery
-
Magali Muller
Biomarker Expert
Check out our lastest job posts:
Scientific Advisors:
-
Vishwa Deep Dixit
Yale University
Innate Immunity -
Christopher Denton
University College London
Fibrosis -
Jörg Distler
Düsseldorf University
Fibrosis -
Erica Herzog
Yale University
Pulmonary Fibrosis -
Brian Feagan
Ontario, Canada
Inflammatory Bowel Disease -
Florian Rieder
Cleveland Clinic
Inflammatory Bowel Disease -
Scott Brian Snapper
Boston/Harvard University
Inflammatory Bowel Disease -
Carrie Sokol
Boston/Harvard University
Type-II Inflammation